Replies to post #107301 on Avid Bioservices Inc (CDMO)

[Protector]

Yes that makes sense.

If there would have been much Bavi into our control arm it's 5.6 months MOS would have been higher because we know as well from the 1mg as from the 3mg arm that the presence of Bavi with docetaxel increases the MOS substantially.

It also means the MOS from the 1mg arm couldn't be much higher then what it was because if only a small amount of Bavi made it from the 1mg arm into the control arm then only a small amount of placebo made it from the control arm into the 1mg arm. (I am assuming a symmetric error here).

That indirectly means that our survival data will not have been impacted a lot and can be relied upon.

[pphmtoolong]

FTM, love your contributions to this board. Are you suggesting that for the 2nd line NSCLC trial the original control arm MOS of 5.6 would have been lower, if the contractors hadn't accidentally given some low dose Bavi to some of them, instead of the placebo?

If so, why would the MOS have been so low compared to the control arm MOS numbers cited in your chart? Do you think that this trial patients represented a sicker group?

TIA,

Paul